Core Viewpoint - The company reported a significant increase in revenue and a reduction in losses for the six months ending June 30, 2025, primarily due to milestone payments from the Elysium licensing agreement [1] Financial Performance - Revenue increased from zero to RMB 45.7 million, representing a 100% increase compared to the same period ending June 30, 2024 [1] - Losses decreased from RMB 169 million to RMB 59 million during the same period [1] Product Development - The company's HER2-STINGiADC clinical candidate, JAB-BX467, is set to be nominated in the second half of 2024, with plans to submit an IND application in 2026 [1] - JAB-BX467 demonstrated good in vitro stability and induced significantly lower peripheral IL-6 levels compared to competitors in preclinical studies [1] - Low-dose administration in cold tumor models effectively inhibited tumor growth and triggered strong immune memory effects upon tumor rechallenge [1] Strategic Partnerships - The company aims to actively seek and establish strategic collaborations with leading multinational companies to enhance the success rate of its drug candidates [1] - These partnerships are intended to leverage complementary expertise and resources to maximize the clinical and commercial value of the company's candidates globally [1]
加科思-B(01167.HK)中期收入增加至4570万元